Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

D. Davis, Ian; Martin, A.; Stockler, M.; Begbie, S.; N. Chi, K.; Chowdhury, Simon; Coskinas, X.; Frydenberg, M.; Hague, W.; Horvath, Lisa; M. Joshua, Anthony; Lawrence, N.; M. Marx, Gavin; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S.; Parnis, F.; Parulekar, W.; Pook, D.; Reaume, M.; Sandhu, Shahneen; Tan, A.; Tan, T.; Thomson, A.; Tu, E.; Vera-Badillo, F.; G Williams, Scott; Yip, S.; Y. Zhang, Alison; Zielinski, R.; J Sweeney, Christopher

doi:10.1056/NEJMoa1903835

Public

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Shared by NobleBlocks on Jun 2, 2019 • 12:00 AM UTC

Authors:

Ian D. Davis

A. Martin

M. Stockler

Abstract

BACKGROUND Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with me...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!